Holocene Advisors LP Invests $47.56 Million in Kymera Therapeutics, Inc. $KYMR

Holocene Advisors LP bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 840,333 shares of the company’s stock, valued at approximately $47,563,000.

Other institutional investors also recently bought and sold shares of the company. Federated Hermes Inc. purchased a new stake in Kymera Therapeutics in the 3rd quarter worth approximately $31,622,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after purchasing an additional 10,052 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of Kymera Therapeutics by 24.4% during the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after purchasing an additional 37,536 shares in the last quarter. Frontier Capital Management Co. LLC lifted its stake in shares of Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after purchasing an additional 359,847 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Kymera Therapeutics by 26.3% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after buying an additional 22,392 shares in the last quarter.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $79.60 on Tuesday. The stock has a market capitalization of $6.50 billion, a PE ratio of -21.63 and a beta of 2.20. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The company has a fifty day moving average of $79.36 and a two-hundred day moving average of $68.77.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.88) EPS. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wells Fargo & Company raised their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Oppenheimer increased their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. raised their target price on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. HC Wainwright lifted their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, UBS Group upped their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $118.90.

Insider Buying and Selling

In other Kymera Therapeutics news, insider Jared Gollob sold 4,895 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total transaction of $417,543.50. Following the completion of the sale, the insider directly owned 117,134 shares in the company, valued at approximately $9,991,530.20. The trade was a 4.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 25,758 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total value of $2,145,641.40. Following the transaction, the chief operating officer directly owned 68,052 shares of the company’s stock, valued at $5,668,731.60. The trade was a 27.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 196,561 shares of company stock worth $17,097,428 in the last quarter. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.